Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical terbinafine hydrochloride versus amorolfine for toenail onychomycosis
2006-003570-10Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Terbinafine in onychomycosis (2 arms), sponsored by Novartis. Primary endpoint: Complete cure rate at week 52. Started Jan 2007; status: completed.
02
Drugs
Terbinafine
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2006-003570-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003570-10.